---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001035"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-06-27T23:59:59+00:00"
generated_at: "2026-06-13T16:06:37.302004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aldeyra Phase 2 ADX-629 in chronic cough meets primary safety endpoint; cough frequency significantly reduced vs placebo

## Summary
- Awake cough frequency reduced vs placebo (P=0.01); 24-hr cough frequency (P=0.001).
- ADX-629 well tolerated; no serious adverse events or discontinuations reported.
- 51 patients enrolled, all completed both treatment periods in crossover design.
- Improvement in LDL and HDL levels observed consistent with prior trials.
- Company to discuss results with regulators; Phase 2 trials in atopic dermatitis and other indications expected 2H 2023.

## SEC filing metadata
- accession: 0001157523-23-001035
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-06-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/0001157523-23-001035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323001035/a53433819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001035
- JSON: https://secwatch.observer/filing/0001157523-23-001035.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.